For many years, the oncology community has desired to treat tumors according to their genetic profile rather than basing treatment solely on the tissue involved. To realize this vision, 'basket' clinical trials are increasingly used to test different tumors in a single trial based on a shared biomarker or mutation. The best example of this, and the first FDA-approved “tissue-agnostic” indication, is Keytruda in MSI-high tumors (approved in 2017). Additional high-profile therapies using the basket trial approach include Loxo Oncology’s LOXO101 in TRK+ tumors, Ignyta’s entrectinib, also in TRK+, and AbbVie’s Rova-T, in DLL3-expressing tumors. The increasing number of tissue-agnostic indications presents several potential challenges and important questions for clinicians, payers, and for industry. Join us for a thought-provoking presentation and discussion on the current landscape for tissue-agnostic oncology products, and implications for stakeholders across the health ecosystem.
5:30 - 6:00 PM Networking
6:00 - 6:10 PM Welcome and opening remarks
6:10 - 6:15 PM Speaker introductions
6:15 - 7:15 PM Panel discussions
7:15 - 7:30 PM Q&A
7:30 - 8:00 PM Closing remarks and additional networking
Event is open to: HBA members and nonmembers
Online registration deadline: 23 October 2018
Onsite (walk-in) registration: Is allowed
*To register onsite, please use a smartphone or other device; show your emailed receipt as proof of registration.
This event is nonrefundable.
1. Understand the clinical pipeline for tissue-agnostic approvals, and identify the tipping point when a sufficient number become available and start to influence the industry
2. Describe how a tumor-agnostic approach would affect some of the systems that exist in the management of oncology
3. Discuss the impact of this trend on various stakeholders in the health ecosystem in the near-term (e.g., HCPs, payers, regulatory, industry, etc.)